Search the Newsreel

DA Davidson raises Cognex stock price target on improved demand outlook

DA Davidson has increased its price target for Cognex (NASDAQ:CGNX) to $65 from $62, while maintaining a Neutral rating, following an improved demand outlook and strong second-quarter 2026 earnings. The firm revised its sales and EPS projections upwards for 2026 and 2027, aligning with …

Cogent Communications Holdings Securities Fraud Class Action Result of Undisclosed Demand and Backlog Issues and Approximately 29% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Kahn Swick & Foti, LLC (KSF) is reminding investors of Cogent Communications Holdings, Inc. (NASDAQ: CCOI) with substantial losses that they have until September 21, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Cogent and its …

CCOI Shareholder Alert: Cogent Communications Holdings, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for investors of Cogent Communications Holdings, Inc. (CCOI), announcing a securities class action lawsuit. The lawsuit alleges that Cogent Communications made materially false or misleading statements regarding its optical wavelength "backlog," customer demand, revenue targets, …

Why Cogent (CCOI) Stock Is Falling Today

Why Cogent (CCOI) Stock Is Falling Today What Happened? Shares of internet service provider Cogent Communications (NASDAQ:CCOI) fell 11.4% in the afternoon session after a weak second-quarter report and a Goldman Sachs price-target cut to $12 from $16. Cogent missed on revenue and EBITDA …

Cognex Corp (CGNX) Shares Fall 3.8% -- What GF Score of 72 Tells Investors

Cognex Corp (CGNX) shares dropped 3.8%, making its current price of $64.36 23.7% above its GF Value of $52.05, suggesting the stock is "Modestly Overvalued." The company has a GF Score of 72/100, indicating an "Above Average" quality, primarily due to strong profitability and …

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Cogent Biosciences reported strong second-quarter 2026 financial results and significant business highlights, including progress toward potential FDA approvals for bezuclastinib for GIST and NonAdvSM later this year. The company also announced the successful onboarding of a cross-functional customer-facing team and a robust pro forma …

Cogent Biosciences (COGT) files prospectus for $400M at-the-market stock program

Cogent Biosciences (COGT) has filed a prospectus supplement for an at-the-market (ATM) stock program, allowing it to offer and sell up to $400 million of its common stock. This program uses an existing automatic shelf registration statement and permits sales through Guggenheim Securities, LLC. …

Cogent Biosciences (NASDAQ: COGT) details cash runway and bezuclastinib FDA timelines

Cogent Biosciences (NASDAQ: COGT) has provided updates on its financial runway and the FDA timelines for its drug bezuclastinib. The company reported a net loss of $96.4 million for Q2 2026, widening from the previous year, but has $792.3 million in cash, cash equivalents, …

Cogent Communications Sees Wavelength Gains but Slower Sprint Integration Payoff

Key Points Interested in Cogent Communications Holdings, Inc.? Here are five stocks we like better. Wavelength services are growing but behind expectations: Revenue increased 68% year over year to a roughly $65 million run rate, though Cogent's goal of capturing 25% of the North …

Cognex Sees Record Revenue, Margin Gains as AI Powers Machine-Vision Growth

Cognex (NASDAQ:CGNX) is experiencing record revenue and margin expansion, driven by strong demand in machine vision and the integration of AI. The company reported record second-quarter revenue of $290 million, with third-quarter guidance projecting another record at $310 million, and has significantly improved its …

CCOI INVESTOR DEADLINE: Cogent Communications Holdings Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against Cogent Communications Holdings (NASDAQ: CCOI) on behalf of investors who purchased stock between February 29, 2024, and May 1, 2026. The lawsuit alleges that Cogent misrepresented its growth prospects by touting …

Cogent Biosciences (NASDAQ:COGT) Shares Gap Down - Time to Sell?

CGNX Q2 Deep Dive: AI-Driven Growth and Product Diversification Shape Outlook

CGNX Q2 Deep Dive: AI-Driven Growth and Product Diversification Shape Outlook Machine vision technology company Cognex (NASDAQ:CGNX) fell short of the market's revenue expectations in Q2 CY2026, but sales rose 16.9% year on year to $291.3 million. On the other hand, next quarter's outlook …

Cogent Biosciences set to report earnings ahead of FDA decisions

Cogent Biosciences is scheduled to report second-quarter earnings, with investors keenly watching for updates on its commercial launch preparations for bezuclastinib, its lead drug candidate, ahead of potential FDA approvals later this year. The company is transitioning from a clinical-stage to a marketed-drug business …

Is Cogent Biosciences Inc (COGT) Worth the Risk After Q2 Earnings Miss? GF Score: 25/100

Don't Overlook Cogent (CCOI) International Revenue Trends While Assessing the Stock

Have you looked into how Cogent Communications (CCOI) performed internationally during the quarter ending June 2026? Considering the widespread global presence of this internet service provider, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth. The …

Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results

Cogent Biosciences Q2 loss widens as bezuclastinib FDA deadlines approach

Cogent Biosciences (COGT) reported a widened net loss of $96.4 million in Q2 2026, up from $73.5 million in Q2 2025, driven by increased R&D and G&A expenses. The company has sufficient cash runway into late 2028 and is approaching key FDA PDUFA dates …

Cogent Biosciences (COGT) widens Q2 loss but nears FDA decisions on bezuclastinib

Cogent Biosciences reported a wider net loss of $96.4 million in Q2 2026, up from $73.5 million in Q2 2025, primarily due to increased R&D and G&A expenses. Despite this, the company is advancing towards potential FDA approvals for bezuclastinib in GIST (November 30, …

Cogent’s Bezuclastinib Could Reach FDA Decisions in Nov., Dec.

Cogent Biosciences reported its Q2 2026 financial results, highlighting significant progress for its drug bezuclastinib with FDA New Drug Applications submitted for GIST and systemic mastocytosis. The company anticipates FDA decisions for GIST by November 30, 2026, and for NonAdvSM by December 30, 2026. …

CCOI Q2 Deep Dive: Margin Expansion and Data Center Monetization Offset Revenue Decline

CCOI Q2 Deep Dive: Margin Expansion and Data Center Monetization Offset Revenue Decline Internet service provider Cogent Communications (NASDAQ:CCOI) fell short of the market's revenue expectations in Q2 CY2026, with sales falling 4.3% year on year to $235.6 million. Its non-GAAP loss of $0.45 …

Cogent Biosciences, Inc. $COGT Shares Sold by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. significantly reduced its stake in Cogent Biosciences (NASDAQ:COGT) by 59.6% in the second quarter, selling 194,697 shares but retaining 131,775 shares valued at approximately $5.1 million. Despite this sale, analyst sentiment for Cogent Biosciences remains positive with a …

Cogent Communications Holdings, Inc. (NASDAQ:CCOI) Given Consensus Rating of "Hold" by Brokerages

Eleven research firms have issued a consensus "Hold" rating for Cogent Communications Holdings, Inc. (NASDAQ:CCOI), with an average 12-month price target of $23.10. While the company beat EPS estimates, its revenue declined year-over-year and analysts predict a full-year loss of $4.25 per share. The …

COGNEX CORP COGNEX ORD SHS (0I14.L) Q1 FY2026 earnings call transcript

Cognex Corporation reported strong Q1 2026 results with a 24% year-over-year revenue increase and a significant expansion in adjusted EBITDA margin to 26.9%. The company raised its Q2 guidance, projecting 16.5% revenue growth, but maintained a cautious full-year outlook due to macroeconomic uncertainties and …

ROSEN, A RANKED AND LEADING FIRM, Encourages Cogent Communications Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CCOI

NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cogent Communications Holdings, Inc. (NASDAQ: CCOI) between February 29, 2024 and May 1, 2026, inclusive (the “Class Period”), of the …

Why Cognex (CGNX) Could Be 17% Undervalued Following Its Raised Outlook

Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cogeco Communications Inc. (TSE:CCA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Cognition Therapeutics Inc (CGTX) Stock News Today

This article provides an overview of Cognition Therapeutics Inc (CGTX) stock information, including its current price, market capitalization, and a note that more news is coming soon. It highlights where to find news, earnings, analyst ratings, and key developments for the company.

Is Cogeco Communications (TSX:CCA) Undervalued On Its $200 Million Notes Offering?

Cogent Communications Holdings, Inc. Securities Fraud Class Action Lawsuit Filed; September 21, 2026, Lead Plaintiff Deadline – Contact Kessler Topaz Meltzer & Check, LLP

Did you buy CCOI common stock between February 29, 2024 and May 1, 2026? Affected CCOI Investor Summary Who: Cogent Communications Holdings, Inc. (NASDAQ: CCOI)What: Securities fraud class action lawsuit filedClass Period: February 29, 2024 through May 1, 2026Deadline to Seek Lead Plaintiff Status: …

Cognition Therapeutics, Inc. (CGTX) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on Cognition Therapeutics, Inc. (CGTX), including its current stock price, historical data, company overview, financial performance, and analyst ratings. CGTX is a clinical-stage biopharmaceutical company developing therapeutics for age-related degenerative diseases, with its lead candidate zervimesine in …

Cognizant Technology Solutions Corp (CTSH) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Assenagon Asset Management S.A. Increases Stock Position in Cogent Biosciences, Inc. $COGT

Assenagon Asset Management S.A. significantly increased its stake in Cogent Biosciences, Inc. (NASDAQ:COGT) by 387.7% in the second quarter, now holding 1.44 million shares valued at $55.8 million. Other major institutional investors like Deerfield Management, RTW Investments, Vanguard, and T. Rowe Price also expanded …

Cogent (CCOI) Stock Falls As Profit Surge Hinges On Asset Sales

Cognition Therapeutics (NASDAQ:CGTX) Releases Earnings Results, Beats Estimates By $0.02 EPS

Cognition Therapeutics (NASDAQ:CGTX) reported a quarterly loss of $0.04 per share, surpassing analysts' consensus estimate by $0.02. Following the earnings release, CGTX shares declined by $0.05 to $1.08. Institutional investors hold 43.35% of the stock, and analysts maintain a "Moderate Buy" consensus rating with …